[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ros1-positive-non-small-cell-lung-cancer-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ros1-positive-non-small-cell-lung-cancer-nsclc":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":4,"overallStatus":22,"whyStopped":4,"lastUpdateSubmitDate":23,"lastUpdatePostDateStruct":24,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":27,"locationsCount":30},"100577366",false,"NCT06797362","Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors","Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement.\n3. Previously received at least 1 prior ROS1 TKI, with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician.\n4. Enrollment in a clinical trial of zidesamtinib is not possible.\n5. Adequate organ function and bone marrow reserve.\n\nExclusion Criteria:\n\n1. Prior receipt of zidesamtinib.\n2. Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol.\n3. Ongoing anti-cancer therapy.\n4. Eligible for ongoing clinical trial with zidesamtinib","ALL","18 Years","EXPANDED_ACCESS","The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.",[20,21],"Non Small Cell Lung Cancer","ROS1-positive Non-Small Cell Lung Cancer (NSCLC)","AVAILABLE","2026-06-11",{"date":25,"type":26},"2026-06-15","ACTUAL",{"name":28,"class":29},"Nuvalent Inc.","INDUSTRY",37,""]